698.00p+0.00 (+0.00%)22 Jul 2024, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo

International Biotechnology Trust PLC Shares News & Articles

Meta spending plans irk investors while Tesla rally sends Nasdaq higher | Wall Street Week

After last week?s market spasm over hints from Fed officials that rates may need to rise rather than fall due to the resilience of the US economy, this week the focus moved on to earnings with around one third of S&P 500 companies posting first-quarter updates.So far most firms have beaten estimates, leading to slim gains for the indices, but an increasing number have tempered their guidance for t

Clarity over new manager gives International Biotechnology Trust a welcome boost

International Biotechnology Trust (IBT) 650pGain to date: 4.8%We said to buy shares in International Biotechnology Trust (IBT) on 1 June 2022 at 620.1p as there was an opportunity to buy cheaply into a sector that had been heavily sold off.Biotech can be a high-risk place to invest and so using an investment trust or fund is often a better way to get exposure as the risks are spread across a portf

RTW Biotech Opportunities has a great track record which isn't reflected in a wide discount to net asset value

Since inception in October 2019 RTW Biotech Opportunities (RTW) has delivered 65.3% growth in NAV (net asset value), smashing the performance of the Russell 2000 Biotech index which is down 0.7% as well as the NBI (Nasdaq Biotech Index) which is up 20.6% over the same period.Despite the superior performance to the benchmark and peers, the shares trade at an unwarranted 23% discount to NAV, represe

Biotech companies in demand as pharmaceutical companies spend billions on takeovers

With so much macroeconomic uncertainty, the recent mergers and acquisitions spree has lost momentum apart from one sector.Big pharmaceutical firms are awash with cash, yet patent cliffs (expiration of patent protection) present challenges which can be partially fixed by buying smaller biotech firms with products almost ready to go to market.International Biotechnology Trust's (IBT) Ailsa Craig and

International Biotechnology Trust manager gives notice to focus on core venture business

- Investment manager wants to terminate contract- Current fund managers to stay on for smooth transition- Likely to be strong interest from other fund managersBiotechnology specialist International Biotechnology Trust (IBT) said investment adviser SV Health Investors had given notice to terminate the management of the trust from 9 February 2024 or earlier if agreed by the parties.SV Health Investo
Showing 1 to 20 of 31